Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: J Heart Lung Transplant. 2018 Oct 1;38(4):408–417. doi: 10.1016/j.healun.2018.09.021

Fig. 4.

Fig. 4.

Two Year Survival with Medical versus LVAD therapy stratified by Patient Profile at Enrollment. (A) Kaplan-Meier survival suggested improved actuarial survival with LVAD versus medical therapy among Profile 4–5 patients. (B) Kaplan-Meier survival was equivalent with medical versus LVAD therapy among Profile 6–7 patients. Medical therapy patients were censored at time of transplant, ventricular assist device placement, or last follow-up. LVAD therapy patients were censored at recovery, transplant, or last follow up. Shaded areas represent 70% confidence intervals.